Journal of Dementia
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Short Article   
  • DEMENTIA, Vol 5(3)

Don’t Let Parkinson’s Defines Human Life

Irene Treacy*
Smovey Health, , Ireland
*Corresponding Author: Irene Treacy, Smovey Health, , Ireland

Received: 03-May-2021 / Editor assigned: 05-May-2021 / Published Date: 25-May-2021

Parkinson's disease is a progressive nervous system condition characterized by tremor, muscle stiffness, and mild, imprecise movement, which mainly affects the elderly and adults. It is linked to brain basal ganglia degeneration and neurotransmitter dopamine deficiency.

It has been observed that dopamine – producing cells known as dopaminergic neurons in the substantia nigra part of the brain – has died according to neurological studies to date that showed that dopamine a neurotransmitter in the brain gradually lowered its rate and that contributes to Parkinson's disease. The progressive nervous system condition influences the movement of people, such as speaking, writing, walking and other voluntary activities, using various treatments for Parkinson's disease but still raising the death rate of Parkinson's disease.

The condition of Parkinson is a progressive neurological movement disorder caused by neurodegeneration. Approximately 10 million people worldwide suffer from Parkinson's disease. In 2012, the global prevalence was about 2.18 million cases worldwide where the US market had $1.15 billion. The Parkinson's disease market in the US is expected to rise from $1.1 billion in sales in 2012 to $2.3 billion in 2022 at a rate of 7.3 percent. Treatment market value is expected to rise from $3.6 billion in 2012 to $5.3 billion in 2022. The US- has the largest market share for Parkinson's clinical disease of 44% by 2022, which is rising from 32% in 2012, led by Japan, Brazil and Germany with 13%, 11% and 10%. Approximately 1 million people in the US have Parkinson's disease, 60,000 of which have been diagnosed annually. Around 127,000 people suffer from PD in the United Kingdom. Male has 50% higher risk than females, but 4 to 5% of patient cases are younger than 40 years and it is known as Parkinson's disease Young-onset.

Major Associations around the globe:

National Parkinson Foundation

American Parkinson Disease Association (APDA)

Parkinson’s disease Foundation

Movement Disorder Society of Australia

Parkinson's Unity Walk

Movement Disorder Society of Japan

Moroccan Neurological Society Movement Disorders Group

Italian Society for the Study of Parkinson Disease, Extrapyramidal

Diseases and Dementia

Ecuador Movement Disorders Group

Austrian Parkinson's Disease Society

Danish Movement Disorder Society

International Parkinson and Movement Disorder Society

Top universities globally working in the field of Parkinson Disease

University of Bath

The University of Queensland University of Bristol

University of Cambridge

The Imperial College of Science and Medicine

Duke University University of Milan

Karolinska Institute

University of Hamburg

The University of Edinburgh

University of Munich

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 977
  • [From(publication date): 0-2021 - Dec 27, 2024]
  • Breakdown by view type
  • HTML page views: 438
  • PDF downloads: 539
Top